effects of fluoxetine with and without omega-3 fatty acid eicosapentaenoic acid on cardiovascular disease risk in depressive patients

Clicks: 215
ID: 230595
2010
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #20 of 62 articles by views in advances in cancer research

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract

Abstract

   INTRODUCTION: Depression seems to be an independent risk factor for cardiovascular disease (CVD). Little is known about the effects of treatment of depression on CAD risk factors. The objective of this study was to determine whether cardiac risk is altered following 8 weeks of treatment of depression with fluoxetine. A secondary aim was to examine whether an omega-3 fatty acid eicosapentaenoic acid (EPA) plus fluoxetine affected the change in CAD risk compared with fluoxetine alone.

   METHODS: Forty patients with a diagnosis of major depression were randomly allocated to receive daily 20 mg fluoxetine plus either 1 g EPA or its placebo for 8 weeks. The 24-item Hamilton Rating Scale for Depression (a validated scoring system usually used in studies of antidepressant medication) was utilized to evaluate clinical symptoms of patients. Cardiac risk was estimated using fasting plasma or serum levels of total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol LDL-C, cortisol and C-reactive protein (CRP) at baseline and at week 8.

   RESULTS: Depression severity was decreased significantly in both groups. CRP and cortisol decreased significantly after treatment. EPA plus fluoxetine did not affect the change in CRP and cortisol compared to fluoxetine alone. Total cholesterol did not change significantly after 8 weeks of treatment. LDL-C/HDL-C ratio increased after treatment without difference between treatment groups.

   CONCLUSIONS: Treatment of patients with major depression by fluoxetine with or without EPA could lower CAD risk due to decreases in cortisol and CRP. Although LDL to HDL ratio increased, its importance in CAD risk is not clear, as LDL size and HDL subclasses were not measured in this study.  EPA plus fluoxetine did not have any significant effect on the change of these risk factors compared to fluoxetine alone in this 8-week trial.

 



  

 


Keywords: cardiovascular disease risk, depression, fluoxetine, omega-3.

Reference Key
djazayeri2010aryaeffects Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Shima Djazayeri;Seyed Ali Keshavarz;Mehdi Tehrani-Doost;Mostafa Hosseini;Mahmoud Jalali;Homayoun Amini;Maryam Chamari;Abolghassem Djazayery
Journal advances in cancer research
Year 2010
DOI
DOI not found
URL
http://arya.mui.ac.ir/index.php/arya/article/view/118
Keywords
Diseases of the circulatory (Cardiovascular) system

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.